These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 26345558)

  • 1. [Management of bone disease in myeloma patients: zoledronic acid or denosumab?].
    Abe M; Miki H; Nakamura S
    Rinsho Ketsueki; 2015 Aug; 56(8):997-1004. PubMed ID: 26345558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
    Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
    Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
    Yee AJ; Raje NS
    Future Oncol; 2018 Feb; 14(3):195-203. PubMed ID: 29052442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
    J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial.
    Raje N; Vadhan-Raj S; Willenbacher W; Terpos E; Hungria V; Spencer A; Alexeeva Y; Facon T; Stewart AK; Feng A; Braun A; Balakumaran A; Roodman GD
    Blood Cancer J; 2016 Jan; 6(1):e378. PubMed ID: 26745852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
    Raje N; Roodman GD; Willenbacher W; Shimizu K; García-Sanz R; Terpos E; Kennedy L; Sabatelli L; Intorcia M; Hechmati G
    J Med Econ; 2018 May; 21(5):525-536. PubMed ID: 29480139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controversies in the use of new bone-modifying therapies in multiple myeloma.
    Terpos E; Ntanasis-Stathopoulos I
    Br J Haematol; 2021 Jun; 193(6):1034-1043. PubMed ID: 33249579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
    Musto P; Petrucci MT; Bringhen S; Guglielmelli T; Caravita T; Bongarzoni V; Andriani A; D'Arena G; Balleari E; Pietrantuono G; Boccadoro M; Palumbo A;
    Cancer; 2008 Oct; 113(7):1588-95. PubMed ID: 18683218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Saridakis ZG; Digkas D; Bisbinas I; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
    Osteoporos Int; 2015 Oct; 26(10):2521-7. PubMed ID: 25990355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
    Kajizono M; Sada H; Sugiura Y; Soga Y; Kitamura Y; Matsuoka J; Sendo T
    Biol Pharm Bull; 2015; 38(12):1850-5. PubMed ID: 26632176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence with denosumab and zoledronic acid among older women: a population-based cohort study.
    Tremblay É; Perreault S; Dorais M
    Arch Osteoporos; 2016 Dec; 11(1):30. PubMed ID: 27679503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries.
    Body JJ; Gatta F; De Cock E; Tao S; Kritikou P; Wimberger P; Mebis J; Peeters M; Pedrazzoli P; Caraceni A; Adamo V; Hechmati G
    Support Care Cancer; 2017 Sep; 25(9):2823-2832. PubMed ID: 28429148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review.
    Mateos MV; Fink L; Koneswaran N; Intorcia M; Giannopoulou C; Niepel D; Cavo M
    BMC Cancer; 2020 Mar; 20(1):170. PubMed ID: 32126974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab: benefits of RANK ligand inhibition in cancer patients.
    Lipton A; Jacobs I
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion.
    Body JJ; von Moos R; Niepel D; Tombal B
    BMC Urol; 2018 Sep; 18(1):81. PubMed ID: 30236112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inhibition of RANK ligand to treat bone metastases].
    Body JJ
    Bull Cancer; 2013 Nov; 100(11):1207-13. PubMed ID: 24158618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab and bone metastases. No better than a bisphosphonate.
    Prescrire Int; 2012 Sep; 21(130):204-6. PubMed ID: 23016249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients.
    Dranitsaris G; Hatzimichael E
    Support Care Cancer; 2012 Jul; 20(7):1353-60. PubMed ID: 22539050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
    Scagliotti GV; Hirsh V; Siena S; Henry DH; Woll PJ; Manegold C; Solal-Celigny P; Rodriguez G; Krzakowski M; Mehta ND; Lipton L; García-Sáenz JA; Pereira JR; Prabhash K; Ciuleanu TE; Kanarev V; Wang H; Balakumaran A; Jacobs I
    J Thorac Oncol; 2012 Dec; 7(12):1823-1829. PubMed ID: 23154554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trials define anti-tumor effects of anti-resorptive agents: denosumab ahead of zoledronate 2 to 1.
    Weintraub B
    BioDrugs; 2011 Apr; 25(2):135-8. PubMed ID: 21443276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.